RxDoctor Payments Data

Adam Lammly, DO

Internal Medicine · Albany, NYNPI 1346535499

Payments from drug & device makers

$1,246in general payments, 2019–2025

Across 57 payments — averaging $21.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$234
  • AstraZeneca$178
  • Amgen$125
  • Regeneron Healthcare Solutions, Inc.$116
  • GSK$75
  • Lilly USA, LLC$73
  • plus $446 from 15 others

What the payments were for

  • Food & beverage$1,246100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,246 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$113,194
Medicare patients
489
Services billed
2,046

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$136,385
JanuviaSitagliptin Phosphate55$81,388
EliquisApixaban55$67,187
JardianceEmpagliflozin23$31,853
TrulicityDulaglutide14$28,695
FarxigaDapagliflozin Propanediol16$20,969
MyrbetriqMirabegron26$19,316
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$14,840
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$14,421
Atorvastatin Calcium906$10,119
SynthroidLevothyroxine Sodium115$9,944
SymbicortBudesonide/Formoterol Fumarate23$8,245
Levothyroxine Sodium409$7,948
Omeprazole501$7,299
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$234$136,38598 claims
MerckJanuvia$26$81,38855 claims
PfizerEliquis, Paxlovid$39$69,92375 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$178$43,63554 claims
Lilly USA, LLCTrulicity$73$28,69514 claims
GSKTrelegy Ellipta, Anoro Ellipta$75$20,54926 claims
Astellas Pharma US IncMyrbetriq$21$19,31626 claims
AbbVieSynthroid$32$9,944115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →